Cargando...
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
BACKGROUND: The cardiovascular (CV) safety of linagliptin was evaluated in subjects with type 2 diabetes (T2DM). METHODS: Pre-specified patient-level pooled analysis of all available double-blind, randomized, controlled trials, ≥12 weeks’ duration (19 trials, 9459 subjects) of linagliptin versus pla...
Gardado en:
| Publicado en: | Cardiovasc Diabetol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4465456/ https://ncbi.nlm.nih.gov/pubmed/25990013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-015-0215-2 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|